NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues
Top Cited Papers
Open Access
- 1 April 2001
- journal article
- review article
- Published by BMJ in Molecular Pathology
- Vol. 54 (2), 57-79
- https://doi.org/10.1136/mp.54.2.57
Abstract
The CCN family of genes presently consists of six distinct members encoding proteins that participate in fundamental biological processes such as cell proliferation, attachment, migration, differentiation, wound healing, angiogenesis, and several pathologies including fibrosis and tumorigenesis. Whereas CYR61 and CTGF were reported to act as positive regulators of cell growth, NOV (nephroblastoma overexpressed) provided the first example of a CCN protein with negative regulatory properties and the first example of aberrant expression being associated with tumour development. The subsequent discovery of the ELM1, rCOP1, and WISP proteins has broadened the variety of functions attributed to the CCN proteins and has extended previous observations to other biological systems. This review discusses fundamental questions regarding the regulation of CCN gene expression in normal and pathological conditions, and the structural basis for their specific biological activity. After discussing the role of nov and other CCN proteins in the development of a variety of different tissues such as kidney, nervous system, muscle, cartilage, and bone, the altered expression of the CCN proteins in various pathologies is discussed, with an emphasis on the altered expression of nov in many different tumour types such as Wilms's tumour, renal cell carcinomas, prostate carcinomas, osteosarcomas, chondrosarcomas, adrenocortical carcinomas, and neuroblastomas. The possible use of nov as a tool for molecular medicine is also discussed. The variety of biological functions attributed to the CCN proteins has led to the proposal of a model in which physical interactions between the amino and carboxy portions of the CCN proteins modulate their biological activity and ensure a proper balance of positive and negative signals through interactions with other partners. In this model, disruption of the secondary structure of the CCN proteins induced by deletions of either terminus is expected to confer on the truncated polypeptide constitutive positive or negative activities.Keywords
This publication has 76 references indexed in Scilit:
- Identification of Connective Tissue Growth Factor as a Target of WT1 Transcriptional RegulationJournal of Biological Chemistry, 2000
- Characterization of Insulin-Like Growth Factor-Binding Protein-Related Proteins (IGFBP-rPs) 1, 2, and 3 in Human Prostate Epithelial Cells: Potential Roles for IGFBP-rP1 and 2 in Senescence of the Prostatic EpitheliumEndocrinology, 2000
- Connective Tissue Growth Factor: What's in a Name?Molecular Genetics and Metabolism, 2000
- Activation of Protein Kinase C Inhibits the Expression of Connective Tissue Growth FactorBiochemical and Biophysical Research Communications, 2000
- Temporal Expression of the Chondrogenic and Angiogenic Growth Factor CYR61 During Fracture RepairJournal of Bone and Mineral Research, 2000
- The CCN Family of Angiogenic Regulators: The Integrin ConnectionExperimental Cell Research, 1999
- The Connective Tissue Growth Factor/Cysteine- Rich 61/Nephroblastoma Overexpressed (CCN) FamilyEndocrine Reviews, 1999
- Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcomaInternational Journal of Cancer, 1996
- The modular architecture of a new family of growth regulators related to connective tissue growth factorFEBS Letters, 1993
- Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10.The Journal of cell biology, 1991